GCM
BDTX icon

Graham Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Graham Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$100K Sell
54,232
-116,667
-68% -$285K ﹤0.01% 1152
2026
Q1 		$364K Buy
170,899
+84,343
+97% +$201K 0.01% 735
2025
Q4 		$210K Buy
86,556
+50,035
+137% +$177K 0.01% 1025
2025
Q3 		$138K Sell
36,521
-35,499
-49% -$104K ﹤0.01% 1129
2025
Q2 		$179K Buy
+72,020
New +$139K ﹤0.01% 1143
2024
Q1 		– Sell
-85,818
Closed -$241K – 1064
2023
Q4 		$241K Buy
+85,818
New +$201K 0.01% 789

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Graham Capital Management's BDTX Position: Q2 2026 in Review

Graham Capital Management reduced its Black Diamond Therapeutics (BDTX) stake by 68% in Q2 2026, selling an estimated $285K and leaving 54,232 shares worth $100K. The position accounts for ﹤0.01% of the portfolio, ranked #1152.

Graham Capital Management first reported a position in BDTX in Q4 2023 and has held it in 6 quarters since. The position peaked at $364K in Q1 2026. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Graham Capital Management held 54,232 shares of Black Diamond Therapeutics worth $100K as of Q2 2026.
  • Graham Capital Management sold 116,667 Black Diamond Therapeutics shares in Q2 2026, an estimated $285K.
  • Black Diamond Therapeutics made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #1152 holding.
  • Graham Capital Management first reported a position in Black Diamond Therapeutics in Q4 2023 and has held it in 6 quarters since.
  • Graham Capital Management's Black Diamond Therapeutics position peaked at $364K in Q1 2026.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.